摘要
目的 探讨 3- (4,5) -双甲基 - 2 -噻唑 - (2 ,5) -二苯基溴化四氮唑蓝 (MTT)药敏试验法在指导临床胃癌及原发肝癌化疗中的作用。方法 50例胃癌和 45例肝癌 ,分设对照组。在化疗前接受 MTT药敏试验者 ,根据药敏结果指导化疗 ,对照组胃癌 2 3例 ,肝癌 2 0例 ,凭经验化疗。结果 在胃癌中 MTT敏感组有效率为 82 .6% (1 9/ 2 3) ,MTT耐药组和对照组有效率分别为 0 (0 / 4 )及47.8% (1 1 / 2 3) ,差异有显著意义 ;肝癌 MTT敏感组有效率为 75% (1 5/ 2 0 ) ,MTT耐药组和对照组有效率分别为 0 (0 / 5)及 40 % (8/ 2 0 )有显著差异 (P<0 .0 1 )。本研究体外药敏和体内疗效总符合率胃癌和肝癌分别为 85.2 % (1 9+4/ 2 7)和 80 % (1 5+5/ 2 5)。结论 MTT体外药敏试验在指导临床胃癌及原发肝癌的化疗中 ,具有满意的效果。
Objective The predictive value of in vitro MTT assay for chemotherapy to stomach carcinoma and liver cancer patients was studied.Methods Of the 50 stomach carcinoma patients,27 had had MTT assay before chemotherapy.According to the result of the MTT assay,23 patients in MTT sensitive group received chemotherapy.The other 4 patients in MTT resistant group and 23 patients in the control group were given chemotheraphy according to clinician exparience,the same liver cancer 25 cases in MTT,5 in resistant group and 20 in the control group.Results The response rate in MTT sensitive group was 82.6% in stomach carcinoma,75% in liver cancer,respectively.There was statistically significant difference in the sensitive group as compared in the resistant group and in control group.Between in vitro and in vivo,the overall coincident rate was 85.2%(19+4/27) and 80%(15+5/25),respectively.ConclusionThe in vitro MTT assay can predict chemotherapy for stomach and liver carcinoma giving satisfactory results.
出处
《肿瘤防治研究》
CAS
CSCD
2001年第1期37-38,共2页
Cancer Research on Prevention and Treatment
